89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Public ClinicalTrials.gov record NCT05563272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2, Multicenter, Open-Label Study of 89Zr-girentuximab for PET/CT Imaging of Tumors Likely to Express High Levels of CAIX
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Study identification
- NCT ID
- NCT05563272
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 11 participants
Conditions and interventions
Conditions
- Cervical Cancer
- Colorectal Cancer
- Esophageal Cancer
- Gastric Cancer
- Glioblastoma Multiforme
- Cholangiocarcinoma
- Hepatocellular Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Epithelial Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma
- Soft Tissue Sarcoma
- Gastric Adenocarcinoma
- Malignant Mesothelioma (MM)
- Von Hippel Lindau
- Bladder Cancer
- Bladder Urothelial Carcinoma
Interventions
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors Diagnostic Test
Diagnostic Test
Eligibility (public fields only)
- Age range
- 18 Years to 95 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 6, 2023 (Actual)
- Primary completion
- May 9, 2025 (Actual)
- Completion
- May 9, 2025 (Actual)
- Last update posted
- Jul 10, 2025
2023 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles(UCLA) | Los Angeles | California | 90095 | — |
| Biogenix Molecular, LLC | Miami | Florida | 33165 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Munson Medical Center | Traverse City | Michigan | 49684 | — |
| University Hospitals Cleveland Medical Center (UHCMC) | Cleveland | Ohio | 44106 | — |
| Kettering Health Research Institute | Kettering | Ohio | 45429 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15219 | — |
| Austin Radiological Association (ARA) | Austin | Texas | 78705 | — |
| Carilion Clinic | Roanoke | Virginia | 24018 | — |
| Inland Imaging | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05563272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2025 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05563272 live on ClinicalTrials.gov.